Tivic Health Shares Rise After US Agency Meeting on Entolimod Set

MT Newswires Live11-19

Tivic Health Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.

The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.

The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.

Entolimod has received Fast Track and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.

Price: 1.83, Change: +0.32, Percent Change: +21.56

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584688369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 03:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584688369","market":"sh","top_or_hot":-1,"title":"Tivic Health Shares Rise After US Agency Meeting on Entolimod Set","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.</p><p>The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.</p><p>The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.</p><p>Entolimod has received <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.</p><p>Price: 1.83, Change: +0.32, Percent Change: +21.56</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tivic Health Shares Rise After US Agency Meeting on Entolimod Set</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTivic Health Shares Rise After US Agency Meeting on Entolimod Set\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-19 03:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.</p><p>The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.</p><p>The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.</p><p>Entolimod has received <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.</p><p>Price: 1.83, Change: +0.32, Percent Change: +21.56</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TIVC","symbol_name":"Tivic Health Systems, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2584688369","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584688369","pubTimestamp":1763493578,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tivic Health Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiolo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TIVC":"Tivic Health Systems, Inc.","BK4082":"医疗保健设备"},"translate_title":"美国机构就恩托莫德举行会议后，Tivic Health股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TIVC":1},"content_text":"Tivic Health Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.Entolimod has received Fast Track and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.Price: 1.83, Change: +0.32, Percent Change: +21.56","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584688369","isCrawlerRequest":true}